Loading...

Arrowhead Pharmaceuticals

Nasdaq:ARWR
Snowflake Description

Flawless balance sheet with questionable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ARWR
Nasdaq
$3B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Arrowhead Pharmaceuticals has significant price volatility in the past 3 months.
ARWR Share Price and Events
7 Day Returns
3.3%
NasdaqGS:ARWR
2.8%
US Biotechs
0.1%
US Market
1 Year Returns
98.9%
NasdaqGS:ARWR
-5.6%
US Biotechs
1.2%
US Market
ARWR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Arrowhead Pharmaceuticals (ARWR) 3.3% 43.3% 50.4% 98.9% 393.6% 96.5%
US Biotechs 2.8% 1.7% -6% -5.6% 14.4% 9.6%
US Market 0.1% 0.6% 0.9% 1.2% 36.7% 37.9%
1 Year Return vs Industry and Market
  • ARWR outperformed the Biotechs industry which returned -5.6% over the past year.
  • ARWR outperformed the Market in United States of America which returned 1.2% over the past year.
Price Volatility
ARWR
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Arrowhead Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Arrowhead Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $27.89.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Arrowhead Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Arrowhead Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:ARWR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $0.11
NasdaqGS:ARWR Share Price ** NasdaqGS (2019-06-18) in USD $27.89
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.39x
United States of America Market PE Ratio Median Figure of 3,092 Publicly-Listed Companies 17.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Arrowhead Pharmaceuticals.

NasdaqGS:ARWR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ARWR Share Price ÷ EPS (both in USD)

= 27.89 ÷ 0.11

263.09x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arrowhead Pharmaceuticals is overvalued based on earnings compared to the US Biotechs industry average.
  • Arrowhead Pharmaceuticals is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Arrowhead Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGS:ARWR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 263.09x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
0.2%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.11x
United States of America Market PEG Ratio Median Figure of 2,126 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

NasdaqGS:ARWR PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 263.09x ÷ 0.2%

1255.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arrowhead Pharmaceuticals is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Arrowhead Pharmaceuticals's assets?
Raw Data
NasdaqGS:ARWR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $2.13
NasdaqGS:ARWR Share Price * NasdaqGS (2019-06-18) in USD $27.89
United States of America Biotechs Industry PB Ratio Median Figure of 425 Publicly-Listed Biotechs Companies 3.03x
United States of America Market PB Ratio Median Figure of 5,244 Publicly-Listed Companies 1.79x
NasdaqGS:ARWR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ARWR Share Price ÷ Book Value per Share (both in USD)

= 27.89 ÷ 2.13

13.12x

* Primary Listing of Arrowhead Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arrowhead Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Arrowhead Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Arrowhead Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Arrowhead Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
0.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Arrowhead Pharmaceuticals expected to grow at an attractive rate?
  • Arrowhead Pharmaceuticals's earnings growth is positive but not above the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Arrowhead Pharmaceuticals's earnings growth is positive but not above the United States of America market average.
  • Arrowhead Pharmaceuticals's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:ARWR Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:ARWR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 0.2%
NasdaqGS:ARWR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 6.2%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.9%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:ARWR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:ARWR Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-09-30 249 102 1
2022-09-30 205 63 1
2021-09-30 60 -81 2
2020-09-30 89 41 16 5
2019-09-30 165 132 54 6
NasdaqGS:ARWR Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 95 132 10
2018-12-31 47 136 -29
2018-09-30 16 -47 -54
2018-06-30 14 -54 -54
2018-03-31 22 -50 -44
2017-12-31 31 -49 -35
2017-09-30 31 -24 -34
2017-06-30 23 -25 -46
2017-03-31 13 -33 -60
2016-12-31 4 -33 -75
2016-09-30 0 -64 -82
2016-06-30 0 -66 -84

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Arrowhead Pharmaceuticals's earnings are expected to grow by 0.2% yearly, however this is not considered high growth (20% yearly).
  • Arrowhead Pharmaceuticals's revenue is expected to grow by 6.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:ARWR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Arrowhead Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ARWR Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-09-30 0.95 0.95 0.95 1.00
2022-09-30 0.59 0.59 0.59 1.00
2021-09-30 -0.83 -0.46 -1.20 2.00
2020-09-30 0.14 0.17 0.11 2.00
2019-09-30 0.55 0.59 0.50 4.00
NasdaqGS:ARWR Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 0.11
2018-12-31 -0.33
2018-09-30 -0.65
2018-06-30 -0.68
2018-03-31 -0.58
2017-12-31 -0.47
2017-09-30 -0.47
2017-06-30 -0.64
2017-03-31 -0.88
2016-12-31 -1.16
2016-09-30 -1.34
2016-06-30 -1.41

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Arrowhead Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Arrowhead Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Arrowhead Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Arrowhead Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Arrowhead Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Arrowhead Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.
  • Arrowhead Pharmaceuticals has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Arrowhead Pharmaceuticals has become profitable in the last year making it difficult to compare the US Biotechs industry average.
Earnings and Revenue History
Arrowhead Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Arrowhead Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ARWR Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 94.79 9.57 22.50 66.42
2018-12-31 47.29 -29.21 20.84 57.63
2018-09-30 16.14 -54.45 19.11 52.97
2018-06-30 13.60 -54.42 34.96 28.96
2018-03-31 22.22 -44.33 16.31 50.71
2017-12-31 30.55 -35.49 13.35 54.30
2017-09-30 31.41 -34.38 17.50 50.90
2017-06-30 22.73 -45.87 24.88 49.36
2017-03-31 13.42 -59.77 31.53 46.21
2016-12-31 4.48 -74.54 42.22 39.73
2016-09-30 0.16 -81.72 24.91 60.80
2016-06-30 0.17 -84.24 41.06 39.13
2016-03-31 0.26 -80.76 39.60 37.40
2015-12-31 0.26 -88.63 36.34 39.24
2015-09-30 0.38 -91.94 35.24 46.74
2015-06-30 0.38 -89.63 32.15 44.89
2015-03-31 0.30 -85.32 30.35 43.78
2014-12-31 0.30 -70.58 28.42 37.49
2014-09-30 0.18 -58.63 24.78 22.78
2014-06-30 0.18 -49.89 18.86 17.46
2014-03-31 0.18 -44.34 15.58 12.94
2013-12-31 0.18 -37.16 12.63 9.90
2013-09-30 0.29 -31.14 12.06 8.34
2013-06-30 0.29 -22.76 11.65 7.38
2013-03-31 0.29 -24.68 13.94 6.85
2012-12-31 0.28 -23.25 14.26 6.14
2012-09-30 0.15 -21.13 14.46 5.03
2012-06-30 0.10 -18.59 13.51 1.85

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Arrowhead Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Arrowhead Pharmaceuticals used its assets less efficiently than the US Biotechs industry average last year based on Return on Assets.
  • Arrowhead Pharmaceuticals has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Arrowhead Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Arrowhead Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Arrowhead Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Arrowhead Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Arrowhead Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Arrowhead Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Arrowhead Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Arrowhead Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Arrowhead Pharmaceuticals Company Filings, last reported 2 months ago.

NasdaqGS:ARWR Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 200.64 0.00 218.20
2018-12-31 171.50 0.00 243.75
2018-09-30 95.24 2.33 76.53
2018-06-30 101.76 2.38 60.48
2018-03-31 113.72 2.43 91.54
2017-12-31 70.20 2.48 50.70
2017-09-30 80.87 2.53 65.61
2017-06-30 89.54 2.58 75.14
2017-03-31 93.34 2.63 86.63
2016-12-31 97.21 2.68 102.11
2016-09-30 95.02 2.73 85.37
2016-06-30 59.43 3.32 44.65
2016-03-31 73.93 0.65 61.46
2015-12-31 92.37 0.70 76.60
2015-09-30 109.62 0.76 98.75
2015-06-30 130.74 0.81 110.53
2015-03-31 144.20 0.87 116.01
2014-12-31 145.71 0.92 127.52
2014-09-30 165.99 1.02 154.16
2014-06-30 185.81 1.08 162.18
2014-03-31 189.54 2.13 160.65
2013-12-31 80.91 2.28 75.63
2013-09-30 25.73 2.30 28.14
2013-06-30 33.31 2.31 33.08
2013-03-31 3.76 2.32 3.31
2012-12-31 7.60 2.43 2.99
2012-09-30 8.81 2.44 3.48
2012-06-30 8.45 2.34 2.39
  • Arrowhead Pharmaceuticals has no debt.
  • Arrowhead Pharmaceuticals has no debt compared to 5 years ago when it was 1.1%.
  • Arrowhead Pharmaceuticals has no debt, it does not need to be covered by operating cash flow.
  • Arrowhead Pharmaceuticals has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Arrowhead Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Arrowhead Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Arrowhead Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Arrowhead Pharmaceuticals dividends.
If you bought $2,000 of Arrowhead Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Arrowhead Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Arrowhead Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:ARWR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:ARWR Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-09-30
2022-09-30
2021-09-30
2020-09-30
2019-09-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Arrowhead Pharmaceuticals has not reported any payouts.
  • Unable to verify if Arrowhead Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Arrowhead Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Arrowhead Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Arrowhead Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Arrowhead Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Arrowhead Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Arrowhead Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Anzalone
COMPENSATION $1,619,901
AGE 49
TENURE AS CEO 11.5 years
CEO Bio

Dr. Christopher R. Anzalone, also known as Chris, Ph.D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer of Calando Pharmaceuticals, Inc. Dr. Anzalone serves as a Director at Unidym, Inc. Dr. Anzalone was the Founder Benet Group, LLC and served as its Chief Executive Officer since 1999 until 2003. He serves as Chief Executive Officer of Tego, Leonardo and Ablaris Therapeutics. He focuses on creating and building new nano-biotechnology companies from university-generated science. He has a wealth of experience in nanotechnology, biotechnology, company-building, biomedical research, investment banking, financial services and venture capital. He is the founding Chief Executive Officer of Nanotope Inc. Dr. Anzalone is also the founding Chief Executive Officer of Leonardo Biosystems. Prior to Benet, Dr. Anzalone was a Partner at Galway Partners, LLC in Washington DC. He joined the firm in 1998 and was involved in sourcing, developing and structuring new business ventures. While at Galway, he was the founding Chief Executive Officer of NanoInk, Inc. He also served as an acting Chief Executive Officer and Chairman for two years at NanoInk. He serves as Chairman and Director of Calando Pharmaceuticals, Inc. He has been a Director of Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He served as a Director of NanoInk, Inc. Before joining Galway, Dr. Anzalone was a National Institutes of Health Fellow at the Smithsonian Institution's Conservation and Research Center Division of the National Zoological Park specializing in embryology and altered germ cell DNA-protein interactions. His research at the Smithsonian and prior to that at the University of California Los Angeles was funded for six years by the NIH. He was an active scientist with publications in the areas of Molecular Biology, Endocrine Physiology, Reproductive Biology and Conservation Biology. Dr. Anzalone is the author of numerous peer-reviewed research publications and has served as a reviewer for international scientific journals. He is the recipient of a number of professional and academic honors and has been a featured speaker at conferences, symposia and research institutions. Dr. Anzalone holds a Ph.D. and an M.A. in Biology from UCLA and a B.A. Government from Lawrence University.

CEO Compensation
  • Chris's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Chris's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Arrowhead Pharmaceuticals management team in years:

9.3
Average Tenure
53
Average Age
  • The average tenure for the Arrowhead Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Chris Anzalone

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
49
TENURE
11.5 yrs

Ken Myszkowski

TITLE
Chief Financial Officer
COMPENSATION
$853K
AGE
52
TENURE
9.3 yrs

Bruce Given

TITLE
Chief Operating Officer
COMPENSATION
$2M
AGE
64
TENURE
7.7 yrs

Patrick O'Brien

TITLE
General Counsel
COMPENSATION
$823K
AGE
54
TENURE
4.5 yrs

Mark Davis

TITLE
Founder and Founder & Director of Insert Therapeutics Inc & Calando

Jane Davidson

TITLE
Head of Human Resources & Administration

Vincent Anzalone

TITLE
Head of Investor Relations & VP

Howard Lovy

TITLE
Director of Communications
TENURE
13.8 yrs

James Hamilton

TITLE
Head of Clinical Development & VP

Susan Boynton

TITLE
Head of Regulatory Affairs
Board of Directors Tenure

Average tenure and age of the Arrowhead Pharmaceuticals board of directors in years:

8.8
Average Tenure
59
Average Age
  • The tenure for the Arrowhead Pharmaceuticals board of directors is about average.
Board of Directors

Doug Given

TITLE
Chairman of the Board
COMPENSATION
$189K
AGE
66

Chris Anzalone

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
49
TENURE
11.5 yrs

Mark Davis

TITLE
Founder and Founder & Director of Insert Therapeutics Inc & Calando

Mike Perry

TITLE
Independent Lead Director
COMPENSATION
$179K
AGE
59

Robert Gish

TITLE
Chairman of Hepatitis B Clinical Advisory Board

Will Waddill

TITLE
Independent Director
COMPENSATION
$131K
AGE
61
TENURE
1.4 yrs

Mauro Ferrari

TITLE
Independent Director
COMPENSATION
$100K
AGE
59
TENURE
8.8 yrs

Stephen Locarnini

TITLE
Member of Hepatitis B Clinical Advisory Board

Ching-Lung Lai

TITLE
Member of Hepatitis B Clinical Advisory Board

Johnson Lau

TITLE
Member of Hepatitis B Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • Arrowhead Pharmaceuticals insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
29. May 19 Sell Patrick O'Brien Individual 28. May 19 28. May 19 -30,000 $24.88 $-746,400
05. Apr 19 Sell Christopher Anzalone Individual 03. Apr 19 03. Apr 19 -50,000 $19.30 $-965,000
11. Jan 19 Sell William Waddill Individual 11. Jan 19 11. Jan 19 -8,500 $14.77 $-125,545
X
Management checks
We assess Arrowhead Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Arrowhead Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Does The Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Share Price Tend To Follow The Market?

(NASDAQ:ARWR), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … The fact that this is well above 1 indicates that its share price movements have shown sensitivity to overall market volatility.

Simply Wall St -

What Kind Of Shareholders Own Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)?

Check out our latest analysis for Arrowhead Pharmaceuticals NasdaqGS:ARWR Ownership Summary, May 21st 2019 What Does The Institutional Ownership Tell Us About Arrowhead Pharmaceuticals? … As you can see, institutional investors own 63% of Arrowhead Pharmaceuticals. … Insider Ownership Of Arrowhead Pharmaceuticals While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.

Simply Wall St -

How Many Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Have Insiders Sold, In The Last Year?

We often see insiders buying up shares in companies that perform well over the long term. … The Last 12 Months Of Insider Transactions At Arrowhead Pharmaceuticals. … Insiders in Arrowhead Pharmaceuticals didn't buy any shares in the last year

Simply Wall St -

Is Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Salary Justified?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Chris Anzalone's Compensation Compare With Similar Sized Companies. … has a market cap of US$1.7b, and is paying total annual CEO compensation of US$1.6m.

Simply Wall St -

Is Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Balance Sheet A Threat To Its Future?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Does ARWR's growth rate justify its decision for financial flexibility over lower cost of capital … Debt funding can be cheaper than issuing new equity due to lower interest cost on debt.

Simply Wall St -

What Kind Of Investor Owns Most Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)?

If you want to know who really controls Arrowhead Pharmaceuticals, Inc. … Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … institutions own shares in the company.

Simply Wall St -

Should You Be Holding Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Right Now?

If you are looking to invest in Arrowhead Pharmaceuticals Inc’s (NASDAQ:ARWR), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your portfolio. … A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … Any stock with a beta of greater than one is considered more volatile than the market, and those with a beta less than one is generally less volatile.

Simply Wall St -

Analysts Expect Breakeven For Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)

Arrowhead Pharmaceuticals Inc's (NASDAQ:ARWR):. … Arrowhead Pharmaceuticals, Inc. … The company’s loss has recently broadened since it announced a -US$34.38m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$44.33m, moving it further away from breakeven?

Simply Wall St -

Market Sentiment Around Loss-Making Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)

Check out our latest analysis for Arrowhead Pharmaceuticals ARWR is bordering on breakeven, according to analysts. … This means that ARWR has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company. … Next Steps: There are too many aspects of ARWR to cover in one brief article, but the key fundamentals for the company can all be found in one place – ARWR’s company page on Simply Wall St.

Simply Wall St -

Arrowhead Pharmaceuticals Inc's (NASDAQ:ARWR) Sustainability In Question?

ARWR has high near term liquidity, with short term assets (cash and other liquid assets) amply covering upcoming one-year liabilities, as well as long-term commitments. … One reason I do like ARWR as a business is its low level of fixed assets on its balance sheet (16.93% of total assets). … ARWR has virtually no fixed assets, which minimizes its downside risk.

Simply Wall St -

Company Info

Description

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Details
Name: Arrowhead Pharmaceuticals, Inc.
ARWR
Exchange: NasdaqGS
Founded: 1989
$2,644,364,858
94,814,086
Website: http://arrowheadpharma.com
Address: Arrowhead Pharmaceuticals, Inc.
225 South Lake Avenue,
Suite 1050,
Pasadena,
California, 91101,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ARWR Common Stock Nasdaq Global Select US USD 13. Jan 2004
DB HDP1 Common Stock Deutsche Boerse AG DE EUR 13. Jan 2004
LSE 0HI3 Common Stock London Stock Exchange GB USD 13. Jan 2004
Number of employees
Current staff
Staff numbers
116
Arrowhead Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/18 23:47
End of day share price update: 2019/06/18 00:00
Last estimates confirmation: 2019/05/28
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.